Los resultados del programa PIONEER demuestran que la semaglutida oral es eficaz, segura y bien tolerada para el control glucmico de pacientes con DM2, incluso en aquellos con ERD, con los beneficios propios de la familia
A healthcare providers assessment and prescription can ensure you get the most benefits at the right time
P.GkeB
By Indication, Type 2 Diabetes mellitus leads the market, due to high prevalence, strong glycemic control, and clinical benefits Type 2 Diabetes Mellitus (T2DM) dominates the GLP-1 receptor agonist market, with a 61.7% share in 2025 , driven by its high global prevalence
As a result of its antioxidant potency, it helps protect the cardiovascular system from free radical damage, while its hypolipidaemic effect plays a part in preventing the accumulation of fat in the arteries
XZ: Methodology, Supervision, Conceptualization, Writing review & editing